ICON Public Limited (NASDAQ:ICLR – Get Rating) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $282.67.
Several equities analysts recently issued reports on ICLR shares. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a research report on Thursday, July 28th. Wells Fargo & Company cut ICON Public from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $280.00 to $250.00 in a research report on Monday, April 25th. Deutsche Bank Aktiengesellschaft upped their price objective on ICON Public from $285.00 to $295.00 in a research report on Friday, July 29th. Citigroup lowered their price objective on ICON Public from $315.00 to $290.00 and set a “buy” rating on the stock in a research report on Friday, July 8th. Finally, Robert W. Baird reiterated a “buy” rating and set a $285.00 target price on shares of ICON Public in a research note on Friday, May 13th.
ICON Public Stock Performance
Shares of ICLR opened at $243.08 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.61. The business’s 50 day moving average price is $219.43 and its 200-day moving average price is $230.39. ICON Public has a 52 week low of $196.34 and a 52 week high of $313.00. The stock has a market cap of $19.78 billion, a P/E ratio of 96.46, a P/E/G ratio of 1.44 and a beta of 0.95.
ICON Public (NASDAQ:ICLR – Get Rating) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.34. The business had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. ICON Public had a return on equity of 10.54% and a net margin of 2.77%. The firm’s quarterly revenue was up 122.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.12 EPS. Equities research analysts anticipate that ICON Public will post 10.61 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ICON Public
Hedge funds and other institutional investors have recently modified their holdings of the stock. Fieldpoint Private Securities LLC increased its stake in shares of ICON Public by 28.3% in the 1st quarter. Fieldpoint Private Securities LLC now owns 2,531 shares of the medical research company’s stock worth $616,000 after purchasing an additional 558 shares in the last quarter. Jag Capital Management LLC purchased a new stake in shares of ICON Public in the 4th quarter worth $206,000. We Are One Seven LLC increased its stake in shares of ICON Public by 2.8% in the 4th quarter. We Are One Seven LLC now owns 7,803 shares of the medical research company’s stock worth $1,122,000 after purchasing an additional 212 shares in the last quarter. Handelsbanken Fonder AB increased its stake in shares of ICON Public by 57.4% in the 1st quarter. Handelsbanken Fonder AB now owns 7,130 shares of the medical research company’s stock worth $1,734,000 after purchasing an additional 2,600 shares in the last quarter. Finally, MAI Capital Management increased its stake in shares of ICON Public by 1.7% in the 1st quarter. MAI Capital Management now owns 4,618 shares of the medical research company’s stock worth $1,123,000 after purchasing an additional 78 shares in the last quarter. 89.41% of the stock is currently owned by hedge funds and other institutional investors.
ICON Public Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Articles
Receive News & Ratings for ICON Public Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ICON Public and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
